Advertisement

P02.12 Immuno-oncology imaging mass cytometry study of the structural and cellular composition of the tumor microenvironment in human cancers

August, 08, 2024 | Select Oncology Journal Articles

Background

High-plex imaging is becoming an increasingly valuable tool to study the tumor microenvironment (TME) in immuno-oncology. The ability to evaluate the multiparametric response in the TME is crucial to predict therapeutic drug efficacy. Particularly, assessment of immunological and oncological processes that dictate tumor growth, metastasis, and immune response are essential for identifying candidates for further clinical evaluation.

Materials and Methods

Imaging Mass Cytometry™ (IMC™) permits analysis of 40-plus distinct tissue and cellular markers simultaneously on tumor samples, providing a thorough evaluation of the spatial landscape of the TME. Application of IMC to study cancer has facilitated important discoveries regarding the interplay of tumor and immunecells in the TME. Here, we demonstrate how our reagents and technology support these applications.

Results

Through systematic selection of human antibodies from both the Maxpar® catalog and Maxpar OnDemand™, we have customized panel kits that permit qualitative and quantitative evaluation of critical tumor pathophysiological parameters. Furthermore, we present a consolidated single-cell analysis (SCA) pipeline by combining the panel kit with the Maxpar IMC Cell Segmentation Kit (ICSK) and present quantitative evaluation of the cellular and structural landscape of theTME in various human cancers.

Conclusions

Overall, customization of the Human Immuno-Oncology IMC Panel Kit successfully defines the tissue architecture of the TME, metastatic and growth potential of tumor cells, and immune cell phenotype and activation in human tumors.

T. Pfister: A. Employment (full or part-time); Significant; Standard BioTools. L. Lim: A. Employment (full or part-time); Significant; Standard BioTools. S. Ouladan: A. Employment (full or part-time); Significant; Standard BioTools. N. Zabinyakov: A. Employment (full or part-time); Significant; Standard BioTools. Q. Raza: A. Employment (full or part-time); Significant; Standard BioTools. C. Loh: A. Employment (full or part-time); Significant; Standard BioTools.

For Additional News from OncWeekly – Your Front Row Seat To The Future of Cancer Care –

Advertisement

LATEST

Advertisement

Sign up for our emails

Trusted insights straight to your inbox and get the latest updates from OncWeekly

Privacy Policy